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Abstract
Background: The commonest opioid used for pain relief in labour is pethidine (meperidine); however, its
effectiveness has long been challenged and the drug has known side effects including maternal sedation, nausea
and potential transfer across the placenta to the foetus. Over a third of women receiving pethidine require an
epidural due to inadequate pain relief. Epidural analgesia increases the risk of an instrumental vaginal delivery and
its associated effects. Therefore, there is a clear need for a safe, effective, alternative analgesic to pethidine. Evidence
suggests that remifentanil patient-controlled analgesia (PCA) reduces epidural conversion rates compared to
pethidine; however, no trial has yet investigated this as a primary endpoint. We are, therefore, comparing pethidine
intramuscular injection to remifentanil PCA in a randomised controlled trial.
Methods/design: Women in established labour, requesting systemic opioid pain relief, will be randomised to either
intravenously administered remifentanil PCA (intervention) or pethidine intramuscular injection (control) in an
unblinded, 1:1 individual randomised trial.
Following informed consent, 400 women in established labour, who request systemic opioid pain relief, from NHS
Trusts across England will undergo a minimised randomisation by a computer or automated telephone system to
either pethidine or remifentanil. In order to balance the groups this minimisation is based on four parameters;
parity (nulliparous versus multiparous), maternal age (<20, 20 < 30, 30 < 40, 40+ years), ethnicity (South Asian
(Pakistani/Indian/Bangladeshi) versus Other) and induced versus spontaneous labour.
The effectiveness of pain relief provided by each technique will be recorded every 30 min after time zero, until
epidural placement, delivery or transfer to theatre, quantified by Visual Analogue Scale. Incidence of maternal side
effects including sedation, delivery mode, foetal distress requiring delivery, neonatal status at delivery and rate of
initiation of breastfeeding within the first hour of birth will also be recorded.
Maternal satisfaction with her childbirth experience will be determined by a postpartum questionnaire prior to
discharge from the delivery ward.
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Discussion: The RESPITE trial’s primary outcome is the proportion of women who have an epidural placed for pain
relief in labour in each arm.
Trial Registration: Current Controlled Trials registration number: ISRCTN29654603. Registered on 23 July 2013.
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Background
Why is there a need to determine epidural conversion
rates for intervention with remifentanil patient-
controlled analgesia or pethidine for pain relief in
labour?
Childbirth can be extremely painful and the provision
of pain relief during labour is a humanitarian duty and a
vital component of a positive maternal experience. The
majority of women who deliver in modern obstetric
units choose a pharmacological method of pain relief,
including Entonox (50% N2O and 50% O2 mixture), the
injection of opioids or neuraxial analgesia by epidural
placement. The commonest opioid used in labour is
pethidine, administered by intramuscular (im) injection
[1]. However, the effectiveness of pain relief provided by
pethidine has long been challenged [2]. Its shortcomings
are more serious when set against known side effects in-
cluding maternal sedation, nausea and potential transfer
across the placenta to the foetus [3]. More than a third
of women who receive pethidine subsequently require
an epidural due to inadequate pain relief [4]. Epidurals
provide highly effective pain relief, but increase the risk
of a forceps or suction delivery [5–7]. Instrumental deliv-
eries are associated with various long-term disadvantages
including increased likelihood of faecal incontinence [8],
sexual dysfunction [9, 10] and extended hospital stay.
Modern ‘low-dose’ epidural regimens reduce this impact
on labour but do not completely mitigate the effect.
Patient-controlled analgesia (PCA) comprises drug
administration via an intravenous drip with a small dose
given each time a woman presses a button, giving her
control over her own pain relief. The pump is pro-
grammed to ensure that the maximum dose allowable is
within the safe range in a given time period. This form
of delivery of pain relief matches the drug dose to pain
sensation within the relevant time frame, which is not
possible using a single-dose im injection [11]. Whilst
PCA is in widespread use for acute pain relief after
surgery it has only a limited role in obstetrics.
Remifentanil is a novel synthetic opioid with a very rapid
onset (blood-brain equilibration 1.2–1.4 min) and short
duration of action (context specific half-life 2–3 min) [12],
giving it an analgesic profile which potentially makes it
effective for providing pain relief over one to two uterine
contractions after a single intravenously administered
dose. It is subject to rapid redistribution and metabolism
by nonspecific blood and tissue esterases, negating the po-
tential for accumulation in mother or foetus [13]. Admin-
istration of remifentanil by PCA has been investigated in
several small studies in comparison to pethidine and been
shown to provide useful, although not complete, pain re-
lief in labour [14–16]. Thus far, there is no evidence of
detrimental neonatal effects in comparison to other opi-
oids [13, 15, 17].
Many UK units offer this form of pain relief in cases
where pain relief is requested, but an epidural is contra-
indicated, for example, in the case of maternal blood
clotting abnormality or platelet dysfunction. However,
the use of remifentanil PCA is not currently widespread
or routine [18]. Crucially, there is some evidence from
the studies performed thus far that the proportion of
women who require rescue pain relief with an epidural
after remifentanil PCA is reduced in comparison to
pethidine [13], although no study has yet investigated
this as a primary endpoint. If such an effect were proven
and remifentanil demonstrated to be at least as safe and
effective as pethidine, the number of women requiring
an epidural in labour could potentially be reduced with a
concomitant beneficial reduction in instrumental vaginal
delivery [5–7] and its associated morbidity.
Numerous clinical studies have examined the effective-
ness of pain relief in labour provided by remifentanil
PCA. These studies have resulted in the refinement of
dose administration techniques to provide the optimum
balance between effectiveness and maternal safety.
An additional table file (see Additional file 1: Table S1)
summarises the pertinent remifentanil studies to date
and gives details on study size, comparator and the rate
of conversion to epidural analgesia, if reported. The
heterogeneity of dosing regimen and the opioid tech-
niques used for comparator are immediately apparent;
however, a degree of consistency in epidural conversion
rate in direction and proportion emerges. It is notable
that the only study which reported a higher epidural
conversion rate with remifentanil used a substantially
smaller drug dose than those in more recent studies
[16]. Thus, inadequate pain relief may have influenced
maternal decisions to request neuraxial blockade.
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Epidural conversion rates of approximately 10% (range
5% to 19%) are commonly reported after remifentanil
PCA regimens using bolus doses of 40 μg or equivalent.
This compares to conversion rates of greater than 30%
(range 17% to 39%) being representative in women
receiving pethidine. A systematic review [19] conducted in
2011, included two studies [4, 20] reporting epidural
conversion rates for remifentanil as half that for pethidine,
with two other studies [16, 21] showing no difference in
progression to epidural.
Methods
Aim
The primary aim of the RESPITE trial is to determine
whether remifentanil PCA, administered for pain relief
in childbirth, reduces the requirement for progression to
epidural analgesia relative to pethidine im injection.
Secondary questions regarding the relative effectiveness
of pain relief, maternal and neonatal indices of wellbeing
and maternal satisfaction will be addressed.
Trial design
RESPITE is a randomised, open-label, multicentre trial
comparing intravenously administered remifentanil PCA
with pethidine im injection in women in established
labour requesting systemic opioid pain relief.
Primary outcome
The primary outcome is the proportion of women who
have an epidural placed for pain relief in labour in each
arm after randomisation. This does not include regional
block (spinal or epidural) sited specifically for the pur-
pose of emergency caesarean section.
Secondary outcomes
 The effectiveness of pain relief provided by each
technique, quantified by Visual Analogue Scale
taken every 30 min after time zero, until epidural
placement, delivery or transfer to theatre
 The incidence of maternal side effects, up to the end
of 3rd stage of labour, including:
Excessive sedation score (not rousable by voice,
sedation score of ≥4)
Oxygen saturation (pulse oximetry) <94%
whilst breathing room air
Nausea requiring antiemetic administration
Requirement and indication for supplemental
oxygen
Respiratory depression (respiratory rate below
eight breaths/min)
 Delivery mode (spontaneous vaginal, instrumental
vaginal, caesarean section)
 Incidence of foetal distress requiring delivery
 Neonatal status at delivery:
Apgar score at 5 min
Incidence of foetal acidosis determined by
umbilical cord gas analysis (if performed)
Requirement for neonatal resuscitation
Incidence of, and indication for, admission to
neonatal care
 Rate of initiation of breastfeeding within the first
hour of birth
 Maternal satisfaction with childbirth experience
determined by postpartum questionnaire prior to
discharge from the delivery ward
Setting
Women will be recruited from multiple (fewer than 10)
NHS trusts across England. Sites are able to participate
in RESPITE if a care pathway is present which allows
eligible women delivering at the site to be randomised
between remifentanil and pethidine.
Eligibility criteria
Women who are admitted to labour ward who fulfil all
the following inclusion criteria and none of the exclusion
criteria will be eligible to be randomised:
Inclusion criteria
 16 years of age or older
 Beyond 37 + 0 weeks’ gestation
 In established labour, defined as regular painful
contractions, irrespective of cervical dilatation, with
vaginal birth intended
 Able to understand all information (written and
oral) presented (using an interpreter if necessary)
and provide signed consent
 Not participating in any other clinical trial of a
medicinal product
 Live, singleton pregnancy with cephalic presentation
 Requesting systemic opioid analgesia
Exclusion criteria
 Contraindication to epidural analgesia
 Contraindication to im injection
 History of a previous adverse reaction to pethidine
or remifentanil
 Patients taking any long-term opioid drug therapy
including methadone
 Systemic opioid pain relief in the last 4 h
administered by intravenous or intramuscular
injection. (Medications administered per os
comprising opioids alone or in combination
preparations, administered in this 4-h period,
are permitted)
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Assessment of eligibility
Under the principles of Good Clinical Practice (GCP),
the decision as to whether a patient is eligible for entry
into a trial is considered to be a medical decision and,
therefore, must be made by a medically qualified doctor.
In the RESPITE study, this decision can be made by an
anaesthetist or an obstetrician, but it is acknowledged
that physicians are not routinely present when a woman
requests opioid analgesia. The responsibility for eligi-
bility assessment can be delegated to a research mid-
wife or nurse and this decision will be made at a
site level following local risk assessment in relation
to the site’s organisation and practice, and should
form part of the feasibility assessment for site ap-
proval. Eligibility for participation will be ratified by
a GCP-trained physician.
Randomisation
Randomisation will be carried out via a web-based
central service (with staffed telephone back-up during
office hours) based at Birmingham Clinical Trials Unit
(BCTU). A 24-h, 7-day, interactive, telephone-based ran-
domisation service will also be provided by the Health
Services Research Unit at the University of Aberdeen.
The web-based central service is only available to those
named on the delegation log, whereas both telephone
services are also available to clinical midwives, nurses
and operating department practitioners (ODPs).
To obtain a randomised allocation and trial number,
the person performing the randomisation process will
need to verify a woman’s date of birth, confirm that all
eligibility criteria have been met and provide the mini-
misation variables. At randomisation a confirmatory
email will be sent to the randomising investigator, the
local principal investigator (PI) and the research midwife/
nurse. A ‘minimisation’ procedure using a computer-based
algorithm will be used to avoid chance imbalances in
parity, an important prognostic variable, which will be
considered as an ordinal variable.
Minimisation variables will be:
1. Parity: nulliparous versus multiparous
2. Maternal age: <20, 20 < 30, 30 < 40, 40+ years.
3. Ethnicity: South Asian (Pakistani/Indian/
Bangladeshi) versus Other
4. Induced versus spontaneous labour
The procedures for randomisation will be fully docu-
mented and tested prior to the start of the trial and
monitored by BCTU.
Pain relief
Women will be randomly allocated in a 1: 1 ratio
to either:
1. Remifentanil PCA (intervention group) or
2. Intramuscular injection of pethidine (control group)
Remifentanil
A dedicated intravenous cannula for remifentanil admin-
istration will be inserted into the woman ’s hand or
forearm. The PCA pump will be preprogrammed by
anaesthetic staff with a regimen to provide a bolus of
40 μg remifentanil with a lockout interval of 2 min. This
dose regimen is based on sample guidelines adapted
from those used in the introduction of remifentanil PCA
into clinical practice in some UK labour wards [22] and
reflects those used in the largest study up to 2010–2011
[20, 23]. In the event of excess sedation being recorded
by regular observation of respiratory function, the regi-
men will be altered by reduction of the remifentanil
bolus dose to 30 μg with a lockout interval of 2 min.
Pethidine
Pethidine will be delivered at a dose of 100 mg by im
injection, up to 4-hourly in frequency, up to a ma-
ximum of four doses, making the maximum dose
400 mg in 24 h.
Intrapartum care
After the administration of analgesia, women will receive
one-to-one midwifery care independent of group alloca-
tion. Clinical observations will be recorded every 30 min
for both monitoring of the women’s status and for trial
purposes, including respiratory rate, continuous oxygen
saturation monitoring by pulse oximetry, numerical sed-
ation score (on a scale of alert to unresponsive) and pain,
using a Visual Analogue Scale pain score of 0 to 100.
The time at which active labour (regular painful con-
tractions and more than 3-cm cervical dilatation) and
second stage (dilatation of at least 10 cm) is diagnosed by
vaginal examination, will be recorded but the degree of
dilatation is not relevant to determination of eligibility.
Indications for contacting a physician anaesthetist are
excessive sedation (not rousable by voice), a respiratory
rate below eight breaths/min or oxygen saturation <94%
despite supplemental inspired oxygen therapy
Women are free to request epidural pain relief at any
point after trial entry. Neither the consenting physician,
research midwife/nurse nor ODP will advise, offer
opinion or be involved with a decision to proceed to epi-
dural. The decision will be taken by a woman parti-
cipating in the study supported by attending clinical
(nonresearch) midwifery staff responsible for their care,
if required. A maternal request for epidural analgesia
will be treated according to local labour ward practice
including assessment by attending midwifery and anaes-
thetic staff. The precise details of epidural technique will
be dictated by local labour ward protocols. In the rare
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instance of epidural placement being recommended for
medical indications arising during labour, this will be
recorded. There is no reason to expect an imbalance of
such an event between allocated groups.
Once effective epidural pain relief is established, the
administration of opioid drugs will be discontinued irre-
spective of trial group allocation. Maternal observations
will be recorded up to the point of epidural placement,
delivery or transfer to operating theatre. Neonatal status
will be recorded at delivery.
Follow-up
The study is primarily confined to the time period
when a woman is in childbirth. Women enter the study
from the time that they request opioid pain relief in
labour and remain in the study for the duration of
labour until both mother and baby have been discharged
from hospital.
The period is, therefore, measured in days. Active data
collection will only occur up to the point of child birth.
There will be a single maternal contact thereafter to
administer a brief questionnaire which includes metrics
of maternal satisfaction. Mean stay in hospital after
spontaneous vaginal delivery is 1–2 days. This period
can be extended if delivery by emergency caesarean
section has been required.
The trial schema which includes eligibility criteria
and outcome measures is shown in Additional file 2:
Figure S1.
Monitoring of all types of adverse event
All types of adverse event which occur to a woman
in the RESPITE trial will be reported as soon as pos-
sible after research staff become aware of the event.
A Serious Adverse Event Form should be completed
as fully as possible and sent via fax or email (from an
NHS account) to the Trials Office. This form will in-
clude an assessment of causality. Upon receipt, the
Trials Office will log details of the adverse event on
that patient’s record on the central trials database and
forward an anonymised copy of the form to the chief
investigator.
Anonymised details of all adverse events will be
presented to the Data Monitoring Committee (DMC)
for scrutiny each time they meet. These anonymised
details will be reported to the Research Ethics Com-
mittee (REC) and Medicines and Healthcare Products
Regulatory Authority (MHRA) annually.
Statistical analysis
Sample size
Epidural conversion rates of approximately 10% (range
5% to 19%) are commonly reported after remifentanil.
This compares to conversion rates of greater than 30%
(range 17% to 39%) being representative in women
receiving pethidine. Taking a deliberately conservative
estimate of intervention effect using these data, a re-
duction in epidural conversion from 30% (pethidine)
to 15% (remifentanil PCA) is reasonable. To detect
such a reduction with 90% power at p = 0.05, would
require 161 women in each arm of the trial, yielding a
sample size of 322 in total. Adjustment must also be
made to account for attrition of the study population
as labour progresses. A proportion of the women will
require urgent delivery, by caesarean section, for foetal
indications before a request for further analgesia can
be made. Assuming that this will not represent more
than 25% of the sample after randomisation (reflecting
the national caesarean section rate) and a 15% emer-
gency caesarean rate is more realistic, a further 48
women will be recruited to offset this attrition of
participants who are not capable of reaching the pri-
mary outcome. Allowing for a modest unavailability of
primary outcome data and nonadherence of 6%, a total
sample size of 400 is, therefore, proposed.
A detailed analysis plan will be developed and agreed
by the TSC and the DMEC. Demographic factors and
clinical characteristics will be summarised with counts
(percentages) for categorical variables, mean (standard
deviation) for normally distributed continuous variables,
or median (interquartile or entire range) for other con-
tinuous variables.
Primary analysis
The primary analysis will be a comparison of the man-
agement policies assigned at randomisation (intention-
to-treat population.) The risk of the primary outcome
in the remifentanil PCA group will be compared with
the group and tested for significance at the two-sided
5% level of significance. In addition to the primary
unadjusted analysis, a log-binomial model will be used
to account for the minimisation variables. Risk ratios
and 95% confidence intervals will be estimated. As the
remifentanil PCA will generally only be available within
the context of the RESPITE trial, we do not anticipate
many protocol deviations; however, a limited incidence
of nonadherence is predicted. The most likely cause
is rapidly progressing labour with delivery occurring
after randomisation, before allocated pain relief can
be administered.
Subgroup analysis
Perception of pain during labour may be influenced by
previous experiences, in particular previous labours, and
this may, in turn, influence the request for epidural.
Maternal parity will, therefore, be prespecified for sub-
group analysis of primary outcome.
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Handling missing data
The extent of missing data for the primary outcome
should be limited, as it is routinely recorded in maternity
records and can be collected retrospectively. The Maternal
Outcome Satisfaction Questionnaire must be completed
before discharge and research nurses/midwives should
make every effort to collect this. Where these time-critical
data are missing, multiple imputation methods may be
considered to inform a sensitivity analysis.
Data management and quality assurance
Data form confidentiality
Personal data and sensitive information required for the
RESPITE trial will be collected directly from trial partici-
pants and hospital notes on paper Data Collection
Forms, coded with the woman’s unique trial number and
initials. Women will be informed about the transfer of
this information to the RESPITE trial office at BCTU
and asked for their consent. All personal information
received in paper format for the trial will be held
securely and treated as strictly confidential according to
BCTU policies. All staff involved in the RESPITE trial
share the same duty of care to prevent unauthorised
disclosure of personal information. No data that could
be used to identify an individual will be published.
Confidentiality of RESPITE database
RESPITE data will be electronically stored and managed
on a dedicated, secure, encrypted trial database, specific-
ally constructed for the purpose. The data will be en-
tered onto a secure computer database, either directly
via the Internet using secure socket layer encryption
technology or indirectly from paper by BCTU staff. The
RESPITE database at BCTU is managed under the pro-
visions of the Data Protection Act and/or applicable laws
and regulations.
Randomisation can be achieved either via the web-
based randomisation module of the trial database, or by
use of a touch-tone activated telephone system, via the
University of Aberdeen, which synchronises with the
RESPITE database.
Access to the randomisation module and data entry
screens of the database will be controlled via individual
username and passwords assigned to research midwives/
nurses and physicians identified on the delegation log as
having responsibility for data collection, and by BCTU
trial staff. Transcription of paper forms on to the RES-
PITE database will be performed either at the site, or the
paper form will be faxed to BCTU.
In-house data quality assurance and validation
The study will adopt a centralised approach to monitor-
ing data quality and compliance. A computer database
will be constructed specifically for the study data and
will include range and logic checks to prevent erroneous
data entry. Independent checking of data entry of paper
questionnaires will be periodically undertaken on small
subsamples. The trial statistician will regularly check the
balance of allocations by the minimisation variables.
Source data verification will only be employed if there is
reason to believe that data quality has been compro-
mised, and then only in a subset of practices.
Long-term storage of data
In line with the impending revision of the Medicines for
Human Use (Clinical Trials) Regulations, once data
collection is complete on all participants, all data will be
stored for at least 25 years. This will allow adequate time
for review and reappraisal, and in particular with the
RESPITE trial, form the basis for further follow-up
research. Any queries or concerns about the data, con-
duct or conclusions of the trial can also be resolved in
this time. Limited data on the participants and records
of any adverse events may be kept for longer if recom-
mended by an independent advisory board.
Trial data will be stored within BCTU under controlled
conditions for at least 3 years after closure. Long-term off-
site data-archiving facilities will be considered for storage
after this time. BCTU has standard processes for both
hard copy and computer database legacy archiving.
Discussion
This protocol describes the RESPITE randomised con-
trolled trial, which will evaluate the effectiveness of
remifentanil intravenously administered PCA compared
with pethidine im injection (the current, standard opioid
analgesic for women in established labour). This will be
assessed by comparing epidural conversion rates in each
study arm. This multicentre study will recruit 400
women in childbirth and the results will be used to
make recommendations on the subsequent adoption of
remifentanil into clinical practice in childbirth via publi-
cations and clinical guidelines.
Many UK units now routinely offer remifentanil PCA
in cases where an epidural is contraindicated and a very
restricted number make it available ‘on demand’ as an
alternative analgesic intervention in labour. Those units
which have pursued adoption into routine practice have
now accumulated the experience of the safe administra-
tion of remifentanil PCA to several thousand women in
childbirth. However, the summary of product character-
istics for remifentanil states that there are insufficient
data to recommend its use in labour or caesarean sec-
tion, so in effect this usage is off label. The challenges of
conducting clinical trials of investigational medicinal
products (CTIMPs) to the standard of GCP required by
regulatory authorities are well-known [24].
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For RESPITE, the use of remifentanil outside its
licenced indication places the trial in a higher-risk
category according to the guidance of the MHRA [25].
This does not necessarily reflect an increased risk to the
trial participants but an acknowledged lack of data.
However, it increases the burden of risk management
and monitoring on those conducting the trial.
Another challenge for RESPITE is the intrapartum re-
cruitment of women in active labour. We have adopted
the recommendation of the RCOG, in which the timing
and extent of the information provided to women is
adapted according to the risk of becoming eligible for
the trial [26]. A considerable proportion of women re-
quire analgesia, so we ensured that all women booked to
deliver at participating hospitals receive information
about the study at the antenatal clinic, during their preg-
nancy and again on admission in labour. The majority of
the eligibility criteria can be determined on admission in
labour. To avoid a situation where consent is sought
from a woman in pain and distress, consent to partici-
pate can be sought from the point that labour is consid-
ered to be established, or is induced, up to and including
the point when the final eligibility criteria, that of
requesting opioid analgesia, is apparent. This allows the
research midwife to fully discuss the trial and gain valid
consent from a woman who is considering participation,
and also prepare the eligibility checklist to enable a
delivery suite midwife to complete the final step of
randomisation if, and when, the request for opioids is
made by the woman. Randomisation may, therefore,
continue even if the research midwife is not present, es-
sential in intrapartum situations. It is widely accepted
that suitably trained research nurses and midwives are
appropriate persons to seek consent for participation in
a clinical trial [27]. Under the principles of GCP, the
decision as to whether a patient is eligible for entry
into a trial is considered to be a medical decision and,
therefore, must be made by a medically qualified doc-
tor. In the RESPITE study, this decision can be made
by an anaesthetist or obstetrician, but it is acknowl-
edged that physicians are not routinely present when a
woman requests opioid analgesia. Indeed, pethidine,
although a controlled drug in UK law, can be inde-
pendently prescribed by a qualified midwife. MHRA
acknowledges that there are certain situations where
the assessment of eligibility can be broadened to in-
clude professionals who are not medically qualified,
such as midwives or nurses. This provision is subject
to the following criteria:
 The role of nonmedical professionals in determining
eligibility has been risk-assessed
 The role of nonmedical professionals is consistent
with standard clinical practice and that
arrangements for the clinical trial should not fall
below that standard
 The duties involved in determining eligibility have
been delegated by an appropriately trained and
qualified member of site staff
 The eligibility assessment process should be
overseen by a medically qualified doctor
It is imperative that the roles and responsibilities are
clarified and communicated with the regulatory aut-
horities prior to the start of any trial facing similar chal-
lenges. This exemption is essential for intrapartum
research and other situations where nonmedical health
care professionals with advanced prescribing responsibil-
ities are the primary care providers.
Trial status
RESPITE is currently recruiting.
Additional files
Additional file 1: Table S1. Previous studies of remifentanil for
analgesia in labour [20, 21, 23, 28]. (XLS 27 kb)
Additional file 2: Figure S1. RESPITE trial schema. (DOC 344 kb)
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